TY - JOUR
T1 - The chemical reactivity of BNP7787 and its metabolite mesna with the cytostatic agent cisplatin
T2 - Comparison with the nucleophiles thiosulfate, DDTC, glutathione and its disulfide GSSG
AU - Verschraagen, Miranda
AU - Kedde, Marc A.
AU - Hausheer, Frederick H.
AU - Van Der Vijgh, Wim J F
PY - 2003/6/1
Y1 - 2003/6/1
N2 - Purpose: BNP7787 is a new chemoprotective agent presently under clinical investigation to protect against cisplatin-induced toxicities, especially nephrotoxicity and neurotoxicity. In the kidneys BNP7787 is postulated to undergo selective conversion into mesna, which can locally detoxify cisplatin. The reactivity of cisplatin with this new chemoprotective agent and with its metabolite mesna was investigated at clinically observed plasma concentrations and compared with the nucleophiles thiosulfate (TS) and DDTC, and with the endogenous compounds glutathione (GSH) and oxidized glutathione (GSSG). Methods: Reaction kinetics experiments were performed at 37°C and pH 7.4 in the presence of a high chloride concentration (0.15 M). The degradation of cisplatin was measured over time using HPLC with off-line flameless atomic absorption spectrophotometry. Results: The degradation half-lives of cisplatin (13.5 μM) with 17.2 mM BNP7787, 340 μM mesna and 17.2 mM mesna were 124 min, about 790 min and 73 min, respectively. Cisplatin reacted at least 9.5 times more slowly with 17.2 mM BNP7787 and 5.5 times more slowly with 17.2 mM mesna than with 17.2 mM of the modulating agents DDTC or TS (i.e. half-lives 11 and 13 min, respectively). The half-lives of cisplatin with 17.2 mM GSH and GSSG (i.e. 122 and 115 min, respectively) were comparable with the half-life obtained with BNP7787. The thiol mesna was shown to be a stronger nucleophile than its corresponding disulfide BNP7787. Conclusions: The much slower relative reactivity of BNP7787, the short residence of BNP7787 (approximately 2 h) and the much lower concentration of mesna in the circulation following BNP7787 administration precludes chemical inactivation of cisplatin in the circulation, and thus the antitumor activity of cisplatin is maintained.
AB - Purpose: BNP7787 is a new chemoprotective agent presently under clinical investigation to protect against cisplatin-induced toxicities, especially nephrotoxicity and neurotoxicity. In the kidneys BNP7787 is postulated to undergo selective conversion into mesna, which can locally detoxify cisplatin. The reactivity of cisplatin with this new chemoprotective agent and with its metabolite mesna was investigated at clinically observed plasma concentrations and compared with the nucleophiles thiosulfate (TS) and DDTC, and with the endogenous compounds glutathione (GSH) and oxidized glutathione (GSSG). Methods: Reaction kinetics experiments were performed at 37°C and pH 7.4 in the presence of a high chloride concentration (0.15 M). The degradation of cisplatin was measured over time using HPLC with off-line flameless atomic absorption spectrophotometry. Results: The degradation half-lives of cisplatin (13.5 μM) with 17.2 mM BNP7787, 340 μM mesna and 17.2 mM mesna were 124 min, about 790 min and 73 min, respectively. Cisplatin reacted at least 9.5 times more slowly with 17.2 mM BNP7787 and 5.5 times more slowly with 17.2 mM mesna than with 17.2 mM of the modulating agents DDTC or TS (i.e. half-lives 11 and 13 min, respectively). The half-lives of cisplatin with 17.2 mM GSH and GSSG (i.e. 122 and 115 min, respectively) were comparable with the half-life obtained with BNP7787. The thiol mesna was shown to be a stronger nucleophile than its corresponding disulfide BNP7787. Conclusions: The much slower relative reactivity of BNP7787, the short residence of BNP7787 (approximately 2 h) and the much lower concentration of mesna in the circulation following BNP7787 administration precludes chemical inactivation of cisplatin in the circulation, and thus the antitumor activity of cisplatin is maintained.
KW - BNP7787
KW - Cisplatin
KW - Glutathione
KW - Mesna
KW - Reaction kinetics
UR - http://www.scopus.com/inward/record.url?scp=0038727868&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0038727868&partnerID=8YFLogxK
M3 - Article
C2 - 12715205
AN - SCOPUS:0038727868
SN - 0344-5704
VL - 51
SP - 499
EP - 504
JO - Cancer Chemotherapy and Pharmacology
JF - Cancer Chemotherapy and Pharmacology
IS - 6
ER -